Letrozole Tablet, Film Coated
Product Images NDC 23155-875

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 23155-875). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avet Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (11005a48 13fd 4c6d A024 1e39e3528e45 01)

Figure-1 (11005a48 13fd 4c6d A024 1e39e3528e45 01)
Chemical structure of Letrozole, showing its molecular framework with two cyanophenyl groups connected to a triazole ring.*
FDA Label Image

Avet.jpg (Avet)

Avet.jpg (Avet)
FDA Label Image

Figure-2 (Figure 1 Disease Free Survival Median Follow Up 73 Months Itt Approach)

Figure-2 (Figure 1 Disease Free Survival Median Follow Up 73 Months Itt Approach)
A Kaplan-Meier survival curve comparing Letrozole and Tamoxifen treatments over 72 months. The y-axis shows survival probability from 0 to 1, and the x-axis shows time in months from 0 to 72. Curves represent patient outcomes with Letrozole and Tamoxifen, including numbers at risk and event rates for each treatment group.*
FDA Label Image

Figure-3 (Figure 2 Kaplan Meier Estimates Of Time To Progression Tamoxifen Study)

Figure-3 (Figure 2 Kaplan Meier Estimates Of Time To Progression Tamoxifen Study)
A Kaplan-Meier survival curve comparing progression-free survival over 60 months between Letrozole 2.5 mg and Tamoxifen 20 mg. The vertical axis indicates progression-free probability, and the horizontal axis indicates time in months. Two lines represent the different treatments, showing trends in progression-free status over time.*
FDA Label Image

Figure-4 (Figure 3 Survival By Randomized Treatment Arm)

Figure-4 (Figure 3 Survival By Randomized Treatment Arm)
A survival curve chart comparing Letrozole and Tamoxifen over a 60-month period. The x-axis represents months, and the y-axis represents the proportion of subjects alive, with Letrozole marked by a solid line and Tamoxifen by a dashed line.*
FDA Label Image

Figure-5 (Figure 4 Kaplan Meier Estimates Of Time To Progression Megestrol Acetate Study)

Figure-5 (Figure 4 Kaplan Meier Estimates Of Time To Progression Megestrol Acetate Study)
A survival curve chart showing time to progression in days on the horizontal axis and probability on the vertical axis. The chart compares three treatment groups: Letrozole 0.5 mg, Letrozole 2.5 mg, and MA (medroxyprogesterone acetate), depicting their progression-free survival over time.*
FDA Label Image

Figure-6 (Figure 5 Kaplan Meier Estimates Of Time To Progression Amino)

Figure-6 (Figure 5 Kaplan Meier Estimates Of Time To Progression Amino)
A line graph depicting time to progression in days for patients treated with Letrozole tablets at doses of 0.5 mg and 2.5 mg. The x-axis represents time to progression in days, ranging from 0 to 900, and the y-axis shows the proportion of progression, ranging from 0 to 1. Multiple lines compare different treatment groups.*
FDA Label Image

Figure 6

Figure 6
Letrozole 2.5 mg film-coated oral tablet by Avet Pharmaceuticals Inc., depicted as a round, orange tablet with imprint "121" on one side and "YL" on the other.*
FDA Label Image

Label (Label 1000s)

Label (Label 1000s)
The label for Letrozole Tablets, USP 2.5 mg by Avet Pharmaceuticals Inc. displays the product name, strength, and dosage form as film-coated tablets. It indicates a package size of 1000 tablets with prescription use only. The label includes color additive information (FD&C Yellow No.5, tartrazine), directions to see package insert for full dosage information, storage instructions, and manufacturer details including Avet Pharmaceuticals Inc. and Beijing Yiling Bio-engineering Technology Co., Ltd. A barcode and revision date of 05/2023 are also visible.*
FDA Label Image

Label 30s.jpg (Label 30s)

Label 30s.jpg (Label 30s)
Label for Letrozole Tablets, USP 2.5 mg by Avet Pharmaceuticals Inc. The film-coated oral tablets contain FD&C Yellow No. 5 (tartrazine) as a color additive. The package contains 30 tablets labeled for prescription use only. The label includes usage directions and storage information, along with manufacturer details and an NDC barcode.*
FDA Label Image

Label 90s.jpg (Label 90s)

Label 90s.jpg (Label 90s)
Label for Letrozole Tablets, USP 2.5 mg by Avet Pharmaceuticals Inc. The film-coated oral tablets come in a package of 90 tablets. The label includes color additive information, storage instructions at 20 to 25°C (68 to 77°F), and manufacturer details in Beijing, China. It also includes warnings to keep out of reach of children, usage only by prescription, and the product NDC 23155-875-09.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.